NeuroBo Pharmaceuticals (NRBO) Competitors $1.60 -0.16 (-9.09%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NRBO vs. OVID, PYRGF, FBLG, AVTE, EPIX, UNCY, PDSB, ANVS, THTX, and RPTXShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Ovid Therapeutics (OVID), PyroGenesis Canada (PYRGF), FibroBiologics (FBLG), Aerovate Therapeutics (AVTE), ESSA Pharma (EPIX), Unicycive Therapeutics (UNCY), PDS Biotechnology (PDSB), Annovis Bio (ANVS), Theratechnologies (THTX), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical preparations" industry. NeuroBo Pharmaceuticals vs. Ovid Therapeutics PyroGenesis Canada FibroBiologics Aerovate Therapeutics ESSA Pharma Unicycive Therapeutics PDS Biotechnology Annovis Bio Theratechnologies Repare Therapeutics Ovid Therapeutics (NASDAQ:OVID) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Is OVID or NRBO more profitable? NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-5,142.56% -39.24% -26.19% NeuroBo Pharmaceuticals N/A -189.12%-122.31% Does the MarketBeat Community believe in OVID or NRBO? Ovid Therapeutics received 327 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 70.80% of users gave Ovid Therapeutics an outperform vote. CompanyUnderperformOutperformOvid TherapeuticsOutperform Votes35470.80% Underperform Votes14629.20% NeuroBo PharmaceuticalsOutperform Votes2775.00% Underperform Votes925.00% Which has stronger valuation & earnings, OVID or NRBO? NeuroBo Pharmaceuticals has lower revenue, but higher earnings than Ovid Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$631.70K112.31-$52.34M-$0.47-2.13NeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/A Which has more risk and volatility, OVID or NRBO? Ovid Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Does the media prefer OVID or NRBO? In the previous week, Ovid Therapeutics had 2 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 2 mentions for Ovid Therapeutics and 0 mentions for NeuroBo Pharmaceuticals. Ovid Therapeutics' average media sentiment score of 1.07 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Ovid Therapeutics Positive NeuroBo Pharmaceuticals Neutral Do institutionals & insiders hold more shares of OVID or NRBO? 72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 13.3% of Ovid Therapeutics shares are held by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend OVID or NRBO? Ovid Therapeutics presently has a consensus target price of $4.04, indicating a potential upside of 304.36%. NeuroBo Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 525.00%. Given NeuroBo Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NeuroBo Pharmaceuticals is more favorable than Ovid Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOvid Therapeutics beats NeuroBo Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.33M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book1.075.094.784.78Net Income-$12.47M$151.83M$120.31M$225.60M7 Day Performance-26.94%-2.13%-1.92%-1.23%1 Month Performance-31.91%-3.10%11.51%3.36%1 Year Performance-53.62%11.54%30.61%16.60% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo Pharmaceuticals1.5303 of 5 stars$1.60-9.1%$10.00+525.0%-45.0%$20.33MN/A0.008Gap DownOVIDOvid Therapeutics4.3809 of 5 stars$1.06+2.4%$4.04+282.9%-71.8%$74.92M$390,000.000.0060Positive NewsPYRGFPyroGenesis CanadaN/A$0.41-1.3%N/A+15.9%$74.54M$9.14M-6.8490FBLGFibroBiologics1.8353 of 5 stars$2.12-4.5%$13.00+513.2%N/A$73.48MN/A0.0010Positive NewsAVTEAerovate Therapeutics1.2441 of 5 stars$2.53flat$2.25-11.1%-86.4%$73.05MN/A-0.8551Short Interest ↓Positive NewsEPIXESSA Pharma3.3486 of 5 stars$1.64flat$9.50+479.3%-73.8%$72.77MN/A-2.6550Earnings ReportPositive NewsGap UpUNCYUnicycive Therapeutics3.3831 of 5 stars$0.70-2.0%$5.13+632.1%+18.3%$72.66M$680,000.00-0.749PDSBPDS Biotechnology1.1339 of 5 stars$1.93+4.9%$11.67+504.5%-66.0%$72.20MN/A-1.5920Analyst ForecastNews CoverageANVSAnnovis Bio2.3121 of 5 stars$5.14-3.2%$32.17+525.8%-59.3%$70.92MN/A-1.193News CoverageTHTXTheratechnologiesN/A$1.54+1.3%N/A+16.2%$70.81M$81.76M-15.20140High Trading VolumeRPTXRepare Therapeutics3.4043 of 5 stars$1.65-6.8%$7.00+324.2%-79.7%$70.14M$51.13M-0.89180High Trading Volume Related Companies and Tools Related Companies Ovid Therapeutics Alternatives PyroGenesis Canada Alternatives FibroBiologics Alternatives Aerovate Therapeutics Alternatives ESSA Pharma Alternatives Unicycive Therapeutics Alternatives PDS Biotechnology Alternatives Annovis Bio Alternatives Theratechnologies Alternatives Repare Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRBO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRBO Stock Alerts